United Therapeutics Corporation Payments to Acquire Debt Securities, Available-for-sale
United Therapeutics Corporation (UTHR) reported Payments to Acquire Debt Securities, Available-for-sale of $770.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $69.10M, a 96.18% decline year-over-year.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $701.70M, a 1.36% increase year-over-year.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $520.30M, a 8.74% increase year-over-year.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $385.90M, a 5.37% decline year-over-year.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for fiscal 2025 was $3.41B, a 106.88% increase from fiscal 2024.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.65B, a 34.53% decline from fiscal 2023.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for fiscal 2023 was $2.51B, a 47.16% increase from fiscal 2022.
- United Therapeutics Corporation payments to acquire debt securities, available-for-sale for fiscal 2022 was $1.71B, a 9.85% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $770.80M 10-Q · filed 2026-08-05 | $1.29B derived: sum of 3 quarters · filed 2026-08-05 | $1.68B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $701.70M 10-Q · filed 2026-05-06 | $1.22B derived: sum of 2 quarters · filed 2026-05-06 | $1.61B derived: sum of 3 quarters · filed 2026-05-06 | $3.41B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $520.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $906.20M derived: sum of 2 quarters · filed 2026-02-25 | $2.71B derived: sum of 3 quarters · filed 2026-08-05 | $3.41B 10-K · filed 2026-02-25 |
| 2025-09-30 | $385.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $2.19B derived: sum of 2 quarters · filed 2026-08-05 | $2.89B 10-Q · filed 2025-10-29 | $3.36B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.81B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.50B 10-Q · filed 2026-08-05 | $2.98B derived: sum of 3 quarters · filed 2026-08-05 | $3.39B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $692.30M 10-Q · filed 2026-05-06 | $1.17B derived: sum of 2 quarters · filed 2026-05-06 | $1.58B derived: sum of 3 quarters · filed 2026-05-06 | $1.81B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $478.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $886.30M derived: sum of 2 quarters · filed 2026-02-25 | $1.12B derived: sum of 3 quarters · filed 2026-02-25 | $1.65B 10-K · filed 2026-02-25 |
| 2024-09-30 | $407.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $638.30M derived: sum of 2 quarters · filed 2025-10-29 | $1.17B 10-Q · filed 2025-10-29 | $1.48B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $230.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $759.80M 10-Q · filed 2025-07-30 | $1.07B derived: sum of 3 quarters · filed 2026-02-25 | $1.71B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $529.30M 10-Q · filed 2025-04-30 | $837.30M derived: sum of 2 quarters · filed 2026-02-25 | $1.48B derived: sum of 3 quarters · filed 2026-02-25 | $2.15B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $308.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $952.80M derived: sum of 2 quarters · filed 2026-02-25 | $1.62B derived: sum of 3 quarters · filed 2026-02-25 | $2.51B 10-K · filed 2026-02-25 |
| 2023-09-30 | $644.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $1.32B derived: sum of 2 quarters · filed 2024-10-30 | $2.21B 10-Q · filed 2024-10-30 | $2.64B derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $672.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $1.56B 10-Q · filed 2024-07-31 | $1.99B derived: sum of 3 quarters · filed 2025-02-26 | $2.26B derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $889.50M 10-Q · filed 2024-05-01 | $1.32B derived: sum of 2 quarters · filed 2025-02-26 | $1.59B derived: sum of 3 quarters · filed 2025-02-26 | $2.12B derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $430.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $700.50M derived: sum of 2 quarters · filed 2025-02-26 | $1.23B derived: sum of 3 quarters · filed 2025-02-26 | $1.71B 10-K · filed 2025-02-26 |
| 2022-09-30 | $270.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $800.50M derived: sum of 2 quarters · filed 2023-11-01 | $1.28B 10-Q · filed 2023-11-01 | $1.77B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $530.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.01B 10-Q · filed 2023-08-02 | $1.50B derived: sum of 3 quarters · filed 2024-02-21 | $2.03B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $477.60M 10-Q · filed 2023-05-03 | $974.50M derived: sum of 2 quarters · filed 2024-02-21 | $1.50B derived: sum of 3 quarters · filed 2024-02-21 | $1.81B derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $496.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $1.03B derived: sum of 2 quarters · filed 2024-02-21 | $1.34B derived: sum of 3 quarters · filed 2024-02-21 | $1.90B 10-K · filed 2024-02-21 |
| 2021-09-30 | $529.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $839.40M derived: sum of 2 quarters · filed 2022-11-02 | $1.40B 10-Q · filed 2022-11-02 | $2.01B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $310.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $869.40M 10-Q · filed 2022-08-03 | $1.48B derived: sum of 3 quarters · filed 2023-02-22 | $2.08B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $559.00M 10-Q · filed 2022-05-04 | $1.17B derived: sum of 2 quarters · filed 2023-02-22 | $1.77B derived: sum of 3 quarters · filed 2023-02-22 | $2.39B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $610.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.21B derived: sum of 2 quarters · filed 2023-02-22 | $1.83B derived: sum of 3 quarters · filed 2023-02-22 | $2.31B 10-K · filed 2023-02-22 |
| 2020-09-30 | $604.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.22B derived: sum of 2 quarters · filed 2021-11-03 | $1.70B 10-Q · filed 2021-11-03 | $2.00B derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $615.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.09B 10-Q · filed 2021-08-04 | $1.39B derived: sum of 3 quarters · filed 2022-02-24 | $1.85B derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $479.20M 10-Q · filed 2021-05-05 | $776.00M derived: sum of 2 quarters · filed 2022-02-24 | $1.23B derived: sum of 3 quarters · filed 2022-02-24 | $1.37B derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $296.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $752.50M derived: sum of 2 quarters · filed 2022-02-24 | $892.00M derived: sum of 3 quarters · filed 2022-02-24 | $1.27B 10-K · filed 2022-02-24 |
| 2019-09-30 | $455.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $595.20M derived: sum of 2 quarters · filed 2020-10-28 | $974.70M 10-Q · filed 2020-10-28 | $1.12B derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $139.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $519.00M 10-Q · filed 2020-07-29 | $663.20M derived: sum of 3 quarters · filed 2021-02-24 | $843.20M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $379.50M 10-Q · filed 2020-04-29 | $523.70M derived: sum of 2 quarters · filed 2021-02-24 | $703.70M derived: sum of 3 quarters · filed 2021-02-24 | $1.06B derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $144.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $324.20M derived: sum of 2 quarters · filed 2021-02-24 | $676.70M derived: sum of 3 quarters · filed 2021-02-24 | $762.70M 10-K · filed 2021-02-24 |
| 2018-09-30 | $180.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $532.50M derived: sum of 2 quarters · filed 2019-10-30 | $618.50M 10-Q · filed 2019-10-30 | $884.30M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $352.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $438.50M 10-Q · filed 2019-07-31 | $704.30M derived: sum of 3 quarters · filed 2020-02-26 | $860.40M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $86.00M 10-Q · filed 2019-05-01 | $351.80M derived: sum of 2 quarters · filed 2020-02-26 | $507.90M derived: sum of 3 quarters · filed 2020-02-26 | $658.70M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $265.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $421.90M derived: sum of 2 quarters · filed 2020-02-26 | $572.70M derived: sum of 3 quarters · filed 2020-02-26 | $718.40M 10-K · filed 2020-02-26 |
| 2017-09-30 | $156.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $306.90M derived: sum of 2 quarters · filed 2018-10-31 | $452.60M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $150.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $296.50M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $145.70M 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |